News | May 28, 2007

Study to Probe Adoption Variables in Atrial Fibrillation Therapy

May 29, 2007 — Frost & Sullivan is launching a new end user study on the state of adoption for atrial fibrillation therapies in the U.S. cardiovascular market. Through more than 150 detailed interviews with electrophysiologists, cardiologists and other cardiovascular professionals, the company aims to elucidate key drivers and obstacles to adoption and utilization of various atrial fibrillation treatments.

"Currently no ablation system to date has been approved explicitly for use in treating atrial fibrillation," notes Frost & Sullivan Industry Analyst Venkat Rajan. "However, advancements in 3-D mapping, other imaging techniques, and features within the systems themselves are enabling higher success rates for procedures. Thereby expanding confidence among end users, and gathering enough clinical data for possible FDA approval."

While there are numerous medical device therapies that are being used to treat atrial fibrillation, such as minimally invasive surgical ablation, catheter ablation, open heart surgery ablation, pacemakers, anticoagulants, etc., physician awareness and preference are often the primary determinants of the method used.

"There are a vast number of participants in the market from start-ups and entrepreneurial-type companies to nearly every major cardiovascular device manufacturer," explains Rajan. "Each manufacturer seems to be attempting to carve out their own niche in the market, whether it is through energy modality, or navigational capabilities."

"Manufacturers that can better understand the drivers and obstacles of adoption and utilization preferences for atrial fibrillation device therapies can develop and refine their technologies to best serve customer demand," says Rajan. "With effective third party information partners, companies can take steps to ensure their continued success."

For more information, visit www.frost.com.

Related Content

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast
News | EP Mapping and Imaging Systems | October 29, 2018
October 29, 2018 — Good Samaritan Hospital recently became the first hospital on the West Coast to utilize the Carto
BioSig Technologies Announces FDA 510(k) Clearance for Pure EP System
Technology | EP Mapping and Imaging Systems | August 14, 2018
BioSig Technologies Inc. announced that the company received 510(k) clearance for its first product, Pure EP System,...
Volta Medical Brings Artificial Intelligence to Cardiac Electrophysiology

Image courtesy of Intermountain Medical Center Heart Institute

News | EP Mapping and Imaging Systems | June 12, 2018
Volta Medical, out of Marseille, France, has developed the first artificial intelligence (AI) software to guide...
APN Health Releases Navik 3D Cardiac Mapping System
Technology | EP Mapping and Imaging Systems | May 03, 2018
May 3, 2018 — APN Health LLC announced its Navik 3D...
Abbott Announces European Launch of Advisor HD Grid Mapping Catheter, Sensor Enabled
Technology | EP Mapping and Imaging Systems | January 19, 2018
Abbott last week announced CE Mark approval for the company's new Advisor HD Grid Mapping Catheter, Sensor Enabled, a...
Videos | EP Mapping and Imaging Systems | October 24, 2017
This video, provided by Acutus Medical, demonstrates a patient case showing the use of the AcQMap high-resolution ele
Acutus Medical Receives FDA Clearance for AcQMap Cardiac Mapping Technology
Technology | EP Mapping and Imaging Systems | October 24, 2017
Acutus Medical announced that the U.S. Food and Drug Administration (FDA) has cleared the AcQMap High Resolution...
Acutus Medical Announces Completion of Enrollment for UNCOVER AF Study
News | EP Mapping and Imaging Systems | May 02, 2017
Acutus Medical recently announced that enrollment has been completed in its pivotal Utilizing Novel Dipole Density...
Videos | EP Mapping and Imaging Systems | February 01, 2017
This video, provided by Medtronic, demonstrates the CardioInsight electro-anatomical mapping system.
Overlay Init